JB Buse, J Rosenstock, G Sesti, WE Schmidt, E … - The Lancet, 2009 - Elsevier Mean baseline HbA 1c for the study population was 8·2%. Liraglutide reduced mean HbA 1c
significantly more than did exenatide (−1·12% [SE 0·08] vs −0·79% [0·08]; estimated treatment
difference −0·33; 95% CI −0·47 to −0·18; p<0·0001) and more patients achieved a HbA 1c ... Cited by 18 - Related articles - All 25 versions
- ►easd.org [PDF] EAM Gale - Diabetologia, 2009 - Springer Drugs for health generate wealth, and wealth drives the diabetes roadshow. Without it, the subsidised
seasonal migrations to our big meetings would grind to a halt, and the KOLs (Key Opinion
Leaders, for the uninitiated) would all be driving a different brand of car. Given that the ... Cited by 1 - Related articles - All 3 versions
J Holst - medscape.com Clinicians, especially primary care providers, are faced with an estimated 20 million Americans
diagnosed with diabetes and approximately 1.5 million new cases each year. Often these patients
have comorbid conditions that only further reduce their long-term heath. The goal of any ... Related articles
JB McGill - jfponline.com Among the treatments available for patients with type 2 diabetes mellitus (T2DM) who do not
achieve or maintain glycemic control with the combination of lifestyle management and metformin
(ie, tier 1/step 1 therapy), 4 other classes of medications are considered preferred ... Related articles - Cached - All 2 versions
J Khoo, CK Rayner, KL Jones, M Horowitz - 2009 - pubmedcentral.nih.gov The advent of 'incretin-based therapies' – GLP-1 agonists and dipeptidyl-peptidase-4 inhibitors
– which result in improvements in glycemic control comparable to those with existing oral hypoglycemic
agents, and potentially improve cardiovascular and pancreatic β-cell function, represents ... Related articles - All 4 versions